{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T02:04:22Z","timestamp":1784253862968,"version":"3.55.0"},"reference-count":32,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,24]],"date-time":"2026-05-24T00:00:00Z","timestamp":1779580800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T00:00:00Z","timestamp":1784246400000},"content-version":"vor","delay-in-days":54,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Mol Cytogenet"],"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Adult T-lymphoblastic leukemia often harbors cryptic structural variants that remain undetected by standard cytogenetic and targeted molecular testing, limiting precise risk stratification and therapeutic planning. This case is notable for the use of optical genome mapping (OGM) to uncover multiple disease-defining and likely oncogenic genomic alterations in an adult patient with newly diagnosed T-lymphoblastic leukemia. The report highlights how comprehensive structural variant profiling can refine prognosis and identify clinically meaningful aberrations that would otherwise be missed in routine practice.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Case presentation<\/jats:title>\n                    <jats:p>\n                      A 29-year-old man presented with fever, chills, dyspnea, headache, petechiae, and was found to have pancytopenia. Bone marrow biopsy showed a hypercellular marrow with approximately 95% involvement by T-lymphoblasts and residual trilineage hematopoiesis. Flow cytometry demonstrated a T-lymphoblastic immunophenotype with expression of cytoplasmic CD3, CD7, terminal deoxynucleotidyl transferase (TdT), absent surface CD3, CD20, CD34, CD117, and myeloperoxidase. Conventional workup with fluorescence in situ hybridization (FISH) initially detected a\n                      <jats:italic>CDKN2A<\/jats:italic>\n                      loss but did not fully define prognosis. OGM revealed a deletion involving\n                      <jats:italic>FBXW7<\/jats:italic>\n                      , a\n                      <jats:italic>TLX3<\/jats:italic>\n                      ::\n                      <jats:italic>BCL11B<\/jats:italic>\n                      fusion (subsequently confirmed by FISH), a hemizygous deletion involving\n                      <jats:italic>PHF6<\/jats:italic>\n                      , a duplication involving\n                      <jats:italic>MYB<\/jats:italic>\n                      , and a deletion involving\n                      <jats:italic>CDKN2A<\/jats:italic>\n                      , while next-generation sequencing identified a\n                      <jats:italic>NOTCH1<\/jats:italic>\n                      missense variant at approximately 50% variant allele fraction. A normal male karyotype was detected at post-induction staging. The patient was counseled on the overall favorable prognostic markers and started on induction therapy using the AALL1231 regimen for T\u2011lymphoblastic leukemia, including protocol-directed incorporation of bortezomib.\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>\n                      OGM revealed multiple clinically relevant structural variants and partner genes impacted in adult T-lymphoblastic leukemia that were not part of the standard cytogenetic workup, thereby improving genomic characterization and risk assessment. Identification of alterations involving\n                      <jats:italic>FBXW7<\/jats:italic>\n                      ,\n                      <jats:italic>NOTCH1<\/jats:italic>\n                      ,\n                      <jats:italic>TLX3<\/jats:italic>\n                      ::\n                      <jats:italic>BCL11B<\/jats:italic>\n                      ,\n                      <jats:italic>PHF6<\/jats:italic>\n                      ,\n                      <jats:italic>MYB<\/jats:italic>\n                      , and\n                      <jats:italic>CDKN2A<\/jats:italic>\n                      provided a comprehensive genomic profile that informed counseling regarding prognosis and supported treatment selection. Integrating OGM into routine evaluation of myeloid and lymphoid neoplasms has the potential to streamline diagnostic workflows and ensure that disease-defining aberrations critical for diagnosis, prognosis, and targeted therapy selection are not overlooked.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.1186\/s13039-026-00770-7","type":"journal-article","created":{"date-parts":[[2026,5,24]],"date-time":"2026-05-24T03:06:20Z","timestamp":1779591980000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Optical genome mapping uncovers disease-defining variants in an adult T-lymphoblastic leukemia and impacts prognosis"],"prefix":"10.1186","volume":"19","author":[{"given":"Amanda M.","family":"Maxfield","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michelle A.","family":"Bickford","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kyle A.","family":"Tonseth","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Bao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Farzana","family":"Murad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Devon N.","family":"Wilson","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lauren M.","family":"Wainman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"John M.","family":"Hill","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Liam L.","family":"Donnelly","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Prabhjot","family":"Kaur","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laura J.","family":"Tafe","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jeremiah X.","family":"Karrs","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wahab A.","family":"Khan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,24]]},"reference":[{"issue":"1","key":"770_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1038\/s41572-024-00525-x","volume":"10","author":"L Pagliaro","year":"2024","unstructured":"Pagliaro L, Chen SJ, Herranz D, Mecucci C, Harrison CJ, Mullighan CG, et al. Acute lymphoblastic leukaemia. Nat Rev Dis Primers. 2024;10(1):1\u201328. https:\/\/doi.org\/10.1038\/s41572-024-00525-x.","journal-title":"Nat Rev Dis Primers"},{"issue":"1","key":"770_CR2","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1002\/hon.2936","volume":"40","author":"Y Hu","year":"2022","unstructured":"Hu Y, Zhang X, Zhang A, Hou Y, Liu Y, Li Q, et al. Global burden and attributable risk factors of acute lymphoblastic leukemia in 204 countries and territories in 1990\u20132019: estimation based on Global Burden of Disease Study 2019. Hematol Oncol. 2022;40(1):93\u2013105. https:\/\/doi.org\/10.1002\/hon.2936.","journal-title":"Hematol Oncol"},{"issue":"4","key":"770_CR3","doi-asserted-by":"publisher","DOI":"10.1002\/cnr2.1369","volume":"4","author":"R Kar","year":"2021","unstructured":"Kar R, Jha SK, Ojha S, Sharma A, Dholpuria S, Raju VSR, et al. The FBXW7-NOTCH interactome: a ubiquitin proteasomal system\u2010induced crosstalk modulating oncogenic transformation in human tissues. Cancer Rep. 2021;4(4):e1369. https:\/\/doi.org\/10.1002\/cnr2.1369.","journal-title":"Cancer Rep"},{"issue":"5130","key":"770_CR4","doi-asserted-by":"publisher","first-page":"110","DOI":"10.1126\/science.8211116","volume":"262","author":"DC Schwartz","year":"1993","unstructured":"Schwartz DC, Li X, Hernandez LI, Ramnarain SP, Huff EJ, Wang YK. Ordered restriction maps of Saccharomyces cerevisiae chromosomes constructed by Optical Mapping. Science. 1993;262(5130):110\u20134. https:\/\/doi.org\/10.1126\/science.8211116.","journal-title":"Science"},{"issue":"12","key":"770_CR5","doi-asserted-by":"publisher","DOI":"10.3390\/genes12121958","volume":"12","author":"P Dremsek","year":"2021","unstructured":"Dremsek P, Schwarz T, Weil B, Malashka A, Laccone F, Neesen J. Optical Genome Mapping in routine human genetic diagnostics\u2014its advantages and limitations. Genes. 2021;12(12):12. https:\/\/doi.org\/10.3390\/genes12121958.","journal-title":"Genes"},{"issue":"5","key":"770_CR6","doi-asserted-by":"publisher","first-page":"548","DOI":"10.1002\/ajh.26487","volume":"97","author":"K Rack","year":"2022","unstructured":"Rack K, De Bie J, Ameye G, Gielen O, Demeyer S, Cools J, et al. Optimizing the diagnostic workflow for acute lymphoblastic leukemia by optical genome mapping. Am J Hematol. 2022;97(5):548\u201361. https:\/\/doi.org\/10.1002\/ajh.26487.","journal-title":"Am J Hematol"},{"issue":"9","key":"770_CR7","doi-asserted-by":"publisher","DOI":"10.3390\/cancers17091436","volume":"17","author":"GA Toruner","year":"2025","unstructured":"Toruner GA, Hu S, Loghavi S, Ok CY, Tang Z, Wei Q, et al. Clinical utility of Optical Genome Mapping as an additional tool in a standard cytogenetic workup in hematological malignancies. Cancers (Basel). 2025;17(9):1436. https:\/\/doi.org\/10.3390\/cancers17091436.","journal-title":"Cancers (Basel)"},{"key":"770_CR8","unstructured":"Shah B, Mattison RJ, Abboud R, Abdelmessieh P, Aldoss I, Burke PW. NCCN Clinical Practice Guidelines in Oncology Acute Lymphoblastic Leukemia Version 1.2024. National Comprehensive Cancer Network; 2024."},{"issue":"19","key":"770_CR9","doi-asserted-by":"publisher","first-page":"1891","DOI":"10.1182\/blood.2023020794","volume":"143","author":"N G\u00f6kbuget","year":"2024","unstructured":"G\u00f6kbuget N, Boissel N, Chiaretti S, Dombret H, Doubek M, Fielding A, et al. Diagnosis, prognostic factors, and assessment of ALL in adults: 2024 ELN recommendations from a European expert panel. Blood. 2024;143(19):1891\u2013902. https:\/\/doi.org\/10.1182\/blood.2023020794.","journal-title":"Blood"},{"issue":"9","key":"770_CR10","doi-asserted-by":"publisher","first-page":"815","DOI":"10.1016\/j.jmoldx.2024.05.013","volume":"26","author":"PS Shah","year":"2024","unstructured":"Shah PS, Hughes EG, Sukhadia SS, Green DC, Houde BE, Tsongalis GJ, et al. Validation and implementation of a somatic-only tumor exome for routine clinical application. J Mol Diagn. 2024;26(9):815\u201324. https:\/\/doi.org\/10.1016\/j.jmoldx.2024.05.013.","journal-title":"J Mol Diagn"},{"issue":"34","key":"770_CR11","doi-asserted-by":"publisher","first-page":"4333","DOI":"10.1200\/JCO.2012.48.5292","volume":"31","author":"A Trinquand","year":"2013","unstructured":"Trinquand A, Tanguy-Schmidt A, Ben Abdelali R, Lambert J, Beldjord K, Lenglin\u00e9 E, et al. Toward a NOTCH1\/FBXW7\/RAS\/PTEN\u2013based oncogenetic risk classification of adult T-cell acute lymphoblastic leukemia: a Group for Research in Adult Acute Lymphoblastic Leukemia study. J Clin Oncol. 2013;31(34):4333\u201342. https:\/\/doi.org\/10.1200\/JCO.2012.48.5292.","journal-title":"J Clin Oncol"},{"issue":"17","key":"770_CR12","doi-asserted-by":"publisher","first-page":"3918","DOI":"10.1182\/blood-2008-10-184069","volume":"113","author":"V Asnafi","year":"2009","unstructured":"Asnafi V, Buzyn A, Le Noir S, Baleydier F, Simon A, Beldjord K, et al. NOTCH1\/FBXW7 mutation identifies a large subgroup with favorable outcome in adult T-cell acute lymphoblastic leukemia (T-ALL): a Group for Research on Adult Acute Lymphoblastic Leukemia (GRAALL) study. Blood. 2009;113(17):3918\u201324. https:\/\/doi.org\/10.1182\/blood-2008-10-184069.","journal-title":"Blood"},{"issue":"15","key":"770_CR13","doi-asserted-by":"publisher","first-page":"1570","DOI":"10.1182\/blood.2023023754","volume":"144","author":"M Simonin","year":"2024","unstructured":"Simonin M, Vasseur L, Lenglin\u00e9 E, Lhermitte L, Cabannes-Hamy A, Balsat M, et al. NGS-based stratification refines the risk stratification in T-ALL and identifies a very-high-risk subgroup of patients. Blood. 2024;144(15):1570\u201380. https:\/\/doi.org\/10.1182\/blood.2023023754.","journal-title":"Blood"},{"key":"770_CR14","doi-asserted-by":"publisher","DOI":"10.1016\/j.humpath.2026.106057","volume":"171","author":"G Tang","year":"2026","unstructured":"Tang G, Wang SA, Jen WY, Medeiros LJ, Wang W, Fang H, et al. Acute leukemia with BCL11B rearrangements: genetic landscape, BCL11B expression, and therapeutic response. Hum Pathol. 2026;171:106057. https:\/\/doi.org\/10.1016\/j.humpath.2026.106057.","journal-title":"Hum Pathol"},{"issue":"6","key":"770_CR15","doi-asserted-by":"publisher","first-page":"344","DOI":"10.1038\/nrclinonc.2015.38","volume":"12","author":"KG Roberts","year":"2015","unstructured":"Roberts KG, Mullighan CG. Genomics in acute lymphoblastic leukaemia: insights and treatment implications. Nat Rev Clin Oncol. 2015;12(6):344\u201357. https:\/\/doi.org\/10.1038\/nrclinonc.2015.38.","journal-title":"Nat Rev Clin Oncol"},{"issue":"1","key":"770_CR16","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1007\/s00428","volume":"482","author":"AS Duffield","year":"2023","unstructured":"Duffield AS, Mullighan CG, Borowitz MJ. International Consensus Classification of Acute Lymphoblastic Leukemia\/Lymphoma. Virchows Arch. 2023;482(1):11\u201326. https:\/\/doi.org\/10.1007\/s00428. 022-03448-8 PubMed PMID: 36422706; PubMed Central PMCID: PMC10646822.","journal-title":"Virchows Arch"},{"issue":"15","key":"770_CR17","doi-asserted-by":"publisher","first-page":"1628","DOI":"10.1101\/gad.17269211","volume":"25","author":"J Zuber","year":"2011","unstructured":"Zuber J, Rappaport AR, Luo W, Wang E, Chen C, Vaseva AV, et al. An integrated approach to dissecting oncogene addiction implicates a Myb-coordinated self-renewal program as essential for leukemia maintenance. Genes Dev. 2011;25(15):1628\u201340. https:\/\/doi.org\/10.1101\/gad.17269211. PubMed PMID: 21828272; PubMed Central PMCID: PMC3182026.","journal-title":"Genes Dev"},{"issue":"10","key":"770_CR18","doi-asserted-by":"publisher","first-page":"2987","DOI":"10.1182\/bloodadvances.2021005955","volume":"6","author":"T Pieters","year":"2022","unstructured":"Pieters T, Almeida A, T\u2019Sas S, Lemeire K, Hochepied T, Berx G, et al. Myb drives B-cell neoplasms and myeloid malignancies in vivo. Blood Adv. 2022;6(10):2987\u201391. https:\/\/doi.org\/10.1182\/bloodadvances.2021005955.","journal-title":"Blood Adv"},{"issue":"5","key":"770_CR19","doi-asserted-by":"publisher","first-page":"593","DOI":"10.1038\/ng2025","volume":"39","author":"I Lahortiga","year":"2007","unstructured":"Lahortiga I, De Keersmaecker K, Van Vlierberghe P, Graux C, Cauwelier B, Lambert F, et al. Duplication of the MYB oncogene in T cell acute lymphoblastic leukemia. Nat Genet. 2007;39(5):593\u20135. https:\/\/doi.org\/10.1038\/ng2025.","journal-title":"Nat Genet"},{"issue":"7","key":"770_CR20","doi-asserted-by":"publisher","first-page":"482","DOI":"10.1002\/gcc.22943","volume":"60","author":"V Bardelli","year":"2021","unstructured":"Bardelli V, Arniani S, Pierini V, Pierini T, Di Giacomo D, Gorello P, et al. MYB rearrangements and over-expression in T-cell acute lymphoblastic leukemia. Genes Chromosomes Cancer. 2021;60(7):482\u20138. https:\/\/doi.org\/10.1002\/gcc.22943.","journal-title":"Genes Chromosomes Cancer"},{"issue":"3","key":"770_CR21","doi-asserted-by":"publisher","first-page":"312","DOI":"10.1002\/ajh.26069","volume":"96","author":"HP Wang","year":"2021","unstructured":"Wang HP, Zhou YL, Huang X, Zhang Y, Qian JJ, Li JH, et al. CDKN2A deletions are associated with poor outcomes in 101 adults with T-cell acute lymphoblastic leukemia. Am J Hematol. 2021;96(3):312\u20139. https:\/\/doi.org\/10.1002\/ajh.26069.","journal-title":"Am J Hematol"},{"key":"770_CR22","doi-asserted-by":"publisher","first-page":"96","DOI":"10.1186\/s13045-018-0639-8","volume":"11","author":"E Genesc\u00e0","year":"2018","unstructured":"Genesc\u00e0 E, Lazarenkov A, Morgades M, Berbis G, Ru\u00edz-Xivill\u00e9 N, G\u00f3mez-Marzo P, et al. Frequency and clinical impact of CDKN2A\/ARF\/CDKN2B gene deletions as assessed by in-depth genetic analyses in adult T cell acute lymphoblastic leukemia. J Hematol Oncol. 2018;11:96. https:\/\/doi.org\/10.1186\/s13045-018-0639-8 . PubMed PMID: 30041662; PubMed Central PMCID: PMC6057006.","journal-title":"J Hematol Oncol"},{"issue":"1","key":"770_CR23","doi-asserted-by":"publisher","DOI":"10.1080\/07853890.2024.2427365","volume":"56","author":"X Hu","year":"2024","unstructured":"Hu X, Xu R, Yu S, Liu Q. A meta-analysis of the prognostic significance of CDKN deletions in acute lymphoblastic leukaemia. Ann Med. 2024;56(1):2427365. https:\/\/doi.org\/10.1080\/07853890.2024.2427365.","journal-title":"Ann Med"},{"issue":"1","key":"770_CR24","doi-asserted-by":"publisher","first-page":"28","DOI":"10.1080\/07853890.2018.1564359","volume":"51","author":"W Zhang","year":"2019","unstructured":"Zhang W, Kuang P, Liu T. Prognostic significance of CDKN2A\/B deletions in acute lymphoblastic leukaemia: a meta-analysis. Ann Med. 2019;51(1):28\u201340. https:\/\/doi.org\/10.1080\/07853890.2018.1564359.","journal-title":"Ann Med"},{"issue":"19","key":"770_CR25","doi-asserted-by":"publisher","first-page":"2106","DOI":"10.1200\/JCO.21.02678","volume":"40","author":"DT Teachey","year":"2022","unstructured":"Teachey DT, Devidas M, Wood BL, Chen Z, Hayashi RJ, Hermiston ML, et al. Children\u2019s Oncology Group trial AALL1231: a phase III clinical trial testing Bortezomib in newly diagnosed T-cell acute lymphoblastic leukemia and lymphoma. J Clin Oncol. 2022;40(19):2106\u201318. https:\/\/doi.org\/10.1200\/JCO.21.02678.","journal-title":"J Clin Oncol"},{"issue":"3","key":"770_CR26","doi-asserted-by":"publisher","DOI":"10.3390\/genes14030686","volume":"14","author":"LM Vieler","year":"2023","unstructured":"Vieler LM, Nilius-Eliliwi V, Schroers R, Vangala DB, Nguyen HP, Gerding WM. Optical genome mapping reveals and characterizes recurrent aberrations and new fusion genes in adult ALL. Genes Basel. 2023;14(3):686. https:\/\/doi.org\/10.3390\/genes14030686.","journal-title":"Genes Basel"},{"issue":"1","key":"770_CR27","doi-asserted-by":"publisher","DOI":"10.3390\/genes17010106","volume":"17","author":"SR Chakraborty","year":"2026","unstructured":"Chakraborty SR, Bickford MA, Smuliac NA, Tonseth KA, Bao J, Murad F, et al. Optical genome mapping enhances structural variant detection and refines risk stratification in chronic lymphocytic leukemia. Genes (Basel). 2026;17(1):106. https:\/\/doi.org\/10.3390\/genes17010106.","journal-title":"Genes (Basel)"},{"issue":"7","key":"770_CR28","doi-asserted-by":"publisher","DOI":"10.3390\/cancers15072131","volume":"15","author":"G Soler","year":"2023","unstructured":"Soler G, Ouedraogo ZG, Goumy C, Lebecque B, Aspas Requena G, Ravinet A, et al. Optical genome mapping in routine cytogenetic diagnosis of acute leukemia. Cancers (Basel). 2023;15(7):2131. https:\/\/doi.org\/10.3390\/cancers15072131.","journal-title":"Cancers (Basel)"},{"issue":"6","key":"770_CR29","doi-asserted-by":"publisher","first-page":"1029","DOI":"10.1002\/ajh.27688","volume":"100","author":"R Kanagal-Shamanna","year":"2025","unstructured":"Kanagal-Shamanna R, Puiggros A, Granada I, Raca G, Rack K, Mallo M, et al. Integration of optical genome mapping in the cytogenomic and molecular work-up of hematological malignancies: expert recommendations from the International Consortium for Optical Genome Mapping. Am J Hematol. 2025;100(6):1029\u201348. https:\/\/doi.org\/10.1002\/ajh.27688.","journal-title":"Am J Hematol"},{"issue":"16","key":"770_CR30","doi-asserted-by":"publisher","first-page":"1729","DOI":"10.1182\/blood-2018-07-860726","volume":"133","author":"HM McRae","year":"2019","unstructured":"McRae HM, Garnham AL, Hu Y, Witkowski MT, Corbett MA, Dixon MP, et al. PHF6 regulates hematopoietic stem and progenitor cells and its loss synergizes with expression of TLX3 to cause leukemia. Blood. 2019;133(16):1729\u201341. https:\/\/doi.org\/10.1182\/blood-2018-07-860726.","journal-title":"Blood"},{"issue":"12","key":"770_CR31","doi-asserted-by":"publisher","first-page":"1808","DOI":"10.3324\/haematol.2011.043083","volume":"96","author":"Q Wang","year":"2011","unstructured":"Wang Q, Qiu H, Jiang H, Wu L, Dong S, Pan J, et al. Mutations of PHF6 are associated with mutations of NOTCH1, JAK1 and rearrangement of SET-NUP214 in T-cell acute lymphoblastic leukemia. Haematologica. 2011;96(12):1808\u201314. https:\/\/doi.org\/10.3324\/haematol.2011.043083 . PubMed PMID: 21880637; PubMed Central PMCID: PMC3232263.","journal-title":"Haematologica"},{"issue":"5","key":"770_CR32","doi-asserted-by":"publisher","DOI":"10.1002\/hem3.70154","volume":"9","author":"M Delafoy","year":"2025","unstructured":"Delafoy M, Balducci E, Simonin M, Pinton A, Charbonnier G, Courtois L, et al. Oncogenomic profiling in infant\u2013toddler T-ALL identifies NKX2 family genes as drivers linked to favorable outcomes. Hemasphere. 2025;9(5):e70154. https:\/\/doi.org\/10.1002\/hem3.70154.","journal-title":"Hemasphere"}],"container-title":["Molecular Cytogenetics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13039-026-00770-7","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13039-026-00770-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13039-026-00770-7.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,17]],"date-time":"2026-07-17T01:48:46Z","timestamp":1784252926000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s13039-026-00770-7"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,24]]},"references-count":32,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["770"],"URL":"https:\/\/doi.org\/10.1186\/s13039-026-00770-7","relation":{},"ISSN":["1755-8166"],"issn-type":[{"value":"1755-8166","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,24]]},"assertion":[{"value":"15 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 May 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"The patient was evaluated and treated under the clinical care protocols of Dartmouth Health. This case report was prepared in accordance with standard clinical care practices. The study was conducted in accordance with the Declaration of Helsinki and approved by the Institutional Review Board (protocol code STUDY02002136).","order":1,"name":"Ethics","label":"Ethics approval and consent to participate","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Patient consent was waived per the IRB as no patient identifying information has been included.","order":2,"name":"Ethics","label":"Consent for publication","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":3,"name":"Ethics","label":"Competing interests","group":{"name":"EthicsHeading","label":"Declarations"}}],"article-number":"27"}}